|
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Clinical research trials and 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma clinical trial. Human subjects often obtain the finest healthcare possible for their 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "5" Clinical Trials Conditions > 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma  506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
For Condition: T-cell childhood acute lymphoblastic leukemia,recurrent adult lymphoblastic lymphoma,T-cell adult acute lymphoblastic leukemia,recurrent adult T-cell leukemia/lymphoma,recurrent childhood lymphoblastic lymphoma,recurrent childhood acute lymphoblastic leukemia,recurrent adult acute lymphoblastic leukemia
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Southwest Oncology Group,Cancer and Leukemia Group B
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma.
Details: OBJECTIVES: I. Determine the complete and partial remission rates, as well as the remission duration, in patients with refractory or relapsed T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma receiving 506U78 on an alternate day schedule (days 1, 3, 5). II. Determine the safety and toxicity of 506U78 administered on this schedule to this patient population. PROTOCOL OUTLINE: Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years. PROJECTED ACCRUAL: Approximately 18-35 patients will be accrued for this study within 2.5-3 years, at a rate of 12-15 patients per year.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed diagnosis of T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) Leukemia or lymphoma cells should express at least two of the following cell surface antigens: CD1a, CD2, CD3 (surface or cytoplasmic), CD4, CD5, CD7, and CD8 Leukemia cells should be negative for myeloperoxidase or Sudan Black B If the only T cell markers present are CD4 and CD7, the leukemic cells should be demonstrated to lack the myeloid markers CD33 and/or CD13 Refractory to at least one induction treatment regimen or in first or later relapse after achieving a complete remission No CNS leukemia or lymphoma requiring intrathecal or craniospinal radiotherapy --Prior/Concurrent Therapy-- Biologic therapy: No concurrent erythropoietin Chemotherapy: See Disease Characteristics No other concurrent chemotherapy Endocrine therapy: No concurrent dexamethasone or other steroidal antiemetics No concurrent hormone therapy, except for non-disease-related conditions Radiotherapy: See Disease Characteristics Surgery: Not specified --Patient Characteristics-- Age: 16 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 times upper limit of normal (unless due to leukemia) Renal: Creatinine clearance at least 50 mL/min (unless due to leukemia) Neurologic: No neurologic toxicity of grade 3 or greater during prior treatment of ALL/LBL No preexisting neuropathy of grade 2 or greater regardless of causality Other: No history of seizure disorder Not pregnant or nursing Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RichardSchilsky, Study Chair, Cancer and Leukemia Group B
David Grant Medical Center
Travis Air Force Base, California, 94535
United States
Oregon Cancer Center
Portland, Oregon, 97201-3098
United States
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410
United States
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
United States
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456
United States
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
United States
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73190
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
United States
CCOP - Columbus
Columbus, Ohio, 43206
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160-7357
United States
CCOP - Columbia River Program
Portland, Oregon, 97213
United States
University of California Davis Medical Center
Sacramento, California, 95817
United States
Stanford University
Stanford, California, 94305
United States
Loyola University Medical Center
Maywood, Illinois, 60153
United States
Texas Tech University Health Science Center
Lubbock, Texas, 79423
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7811
United States
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
United States
Veterans Affairs Medical Center - Phoenix (Hayden)
Phoenix, Arizona, 85012
United States
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, 90073
United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45219
United States
Swedish Cancer Institute
Seattle, Washington, 98104
United States
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
United States
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932
United States
University of Texas Medical Branch
Galveston, Texas, 77555-0209
United States
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
United States
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
United States
CCOP - Dayton
Kettering, Ohio, 45429
United States
CCOP - Southeast Cancer Control Consortium
Winston Salem, North Carolina, 27104-4241
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
United States
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
United States
Henry Ford Hospital
Detroit, Michigan, 48202
United States
CCOP - Scott and White Hospital
Temple, Texas, 76508
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
United States
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
United States
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104
United States
CCOP - Northwest
Tacoma, Washington, 98405-0986
United States
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141
United States
Boston Medical Center
Boston, Massachusetts, 02118
United States
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108
United States
St. Louis University Health Sciences Center
St. Louis, Missouri, 63110-0250
United States
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148
United States
CCOP - Kansas City
Kansas City, Missouri, 64131
United States
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726
United States
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
United States
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288
United States
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
United States
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207
United States
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, 91010-3000
United States
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
United States
Keesler Medical Center - Keesler AFB
Keesler AFB, Mississippi, 39534-2576
United States
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932
United States
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723
United States
CCOP - Central Illinois
Decatur, Illinois, 62526
United States
Tulane University School of Medicine
New Orleans, Louisiana, 70112
United States
CCOP - St. Louis-Cape Girardeau
St. Louis, Missouri, 63141
United States
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218
United States
Madigan Army Medical Center
Tacoma, Washington, 98431-5000
United States
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503
United States
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
United States
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
United States
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975
United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
United States
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323
United States
CCOP - Duluth
Duluth, Minnesota, 55805
United States
University of Colorado Cancer Center
Denver, Colorado, 80010
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
Arizona Cancer Center
Tucson, Arizona, 85724
United States
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
United States
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
United States
CCOP - Greenville
Greenville, South Carolina, 29615
United States
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
United States
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
United States
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504
United States
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
United States
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78284
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154
United States
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
United States
Additional Information:
Study ID Numbers: CDR0000066600; CLB-19801
Study Start Date: April 2000
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003545
Other Recurrent Childhood Acute Lymphoblastic Leukemia Studies:
1. 506U78 in Treating Patients With Refractory Hematologic Cancer
2. Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
3. Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
4. 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Related Studies:
Other recurrent childhood acute lymphoblastic leukemia Clinical Trials
Other California Clinical Trials
Other Orange Clinical Trials
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
|
|
|
|
|
|
|
